checkAd

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting

Nachrichtenquelle: Business Wire (engl.)
12.04.2021, 07:35  |  132   |   |   

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/

Figure 1: Effect of TOTUM•854 supplementation on systolic (SBP) and diastolic (DBP) blood pressure after 3 weeks, in an induced hypertension model (L-NAME model). After 3 weeks, L-NAME induced a 24 mmHg-raise in SBP and a 19 mmHg- raise in DPB (grey bars). Supplementation with TOTUM•854 (blue bars) significantly reduced SBP by 16 mmHg (p<0.01) and DBP by 15 mmHg (p<0.05). (Graphic: Business Wire)

Figure 1: Effect of TOTUM•854 supplementation on systolic (SBP) and diastolic (DBP) blood pressure after 3 weeks, in an induced hypertension model (L-NAME model). After 3 weeks, L-NAME induced a 24 mmHg-raise in SBP and a 19 mmHg- raise in DPB (grey bars). Supplementation with TOTUM•854 (blue bars) significantly reduced SBP by 16 mmHg (p<0.01) and DBP by 15 mmHg (p<0.05). (Graphic: Business Wire)

VALBIOTIS (FR0013254851 – ALVAL, PEA-SME eligible) (Paris:ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the presentation of positive preclinical results of TOTUM•854 in hypertension at the joint meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) held from April 11 to 14, 2021, in virtual format.

This research, conducted on two different in vivo models, shows that TOTUM•854 prevents hypertension.
Based on this positive data, Valbiotis is stepping up its development of TOTUM•854 and will launch three clinical studies at the end of this year, including a Phase II/III clinical study for reduction of hypertension, a risk factor for cardiovascular disease.
TOTUM•854 could be commercialized at the end of this study, up to 3 years ahead of schedule, in partnership with a major healthcare player.

Pascal SIRVENT, Member of the Board and Head of Discovery, Preclinical and Translational Research at Valbiotis, said: “We are proud of this first selection at a major international congress in the cardiovascular field, for which Valbiotis has partnered with the University of Avignon. The TOTUM•854 data collected from two different models of hypertension is remarkable, it validates our hypotheses and our approach to this condition. This very strong proof-of-concept for prevention of hypertension points to ambitious clinical development for TOTUM•854.”

The work presented at the ESH-ISH Joint Meeting was conducted on a model of hypertension induced by L-NAME (a NO synthase inhibitor). In this classic model of hypertension, predictive of human physiology, TOTUM•854 prevented the onset of hypertension compared with the control group. Additional data, obtained from a polygenic model of hypertension (SHR, spontaneously hypertensive rats), also shows a positive effect of TOTUM•854 that delays the onset of hypertension. In addition, a significant acute effect was observed following a single dose of TOTUM•854 on the same SHR model.

Seite 1 von 4
Valbiotis Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/Figure 1: Effect of TOTUM•854 supplementation on systolic (SBP) and diastolic (DBP) blood pressure after 3 …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel